Unit of Immunology and Chronic Disease, Division of Physiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Clin Exp Immunol. 2013 Dec;174(3):441-8. doi: 10.1111/cei.12181.
The risk of premature death is high in haemodialysis (HD) patients. Antibodies against cardiolipin (anti-CL) are thrombogenic in diseases such as systemic lupus erythematosus (SLE). CL is easily oxidized (Ox) and plays a role in apoptosis. In this work we studied immunoglobulin (Ig)M anti-CL and anti-OxCL in HD-patients. We conducted an observational study with a prospective follow-up examining the relationship between anti-CL, anti-OxCL and mortality risk in a well-characterized cohort of 221 prevalent HD patients [56% men, median age 66 (interquartile range 51-74) years, vintage time 29 (15-58) months] with a mean follow-up period of 41 (20-48 months). According to the receiver operator characteristic (ROC) analysis, anti-OxCL [area under the curve (AUC) 0·62, P < 0·01], but not anti-CL (AUC 0·52, P = 0·2), is associated with mortality. In crude and adjusted Cox analysis, every log increase in anti-OxCL inversely predicted all-cause [adjusted hazard ratios (HR) 0·62 (0·43-0·89)] and CVD-related [adjusted HR 0·56 (0·32-0·98)] mortality. Patients with anti-OxCL levels below median also had increased all-cause and cardiovascular disease (CVD)-related mortality. Although anti-OxCL and anti-phosphorylcholine (PC) were related positively to each other (ρ = 0·57, P < 0·01), patients with one or two of these autoantibody levels below the median were associated with an incrementally increased death risk. Anti-OxCL were co-factor β2-GPI-independent; anti-CL from patients with anti-phospholipid antibody syndrome were β2-GPI-dependent, while sera from HD-patients less so. Sera from healthy donors was not β2-GPI-dependent. Anti-OxCL IgM is β2-glycoprotein 1 (GPI)-independent and a novel biomarker; low levels are associated with death among HD patients (and high levels with decreased risk). Combination with anti-PC increases this association. Putative therapeutic implications warrant further investigation.
在血液透析(HD)患者中,过早死亡的风险很高。抗心磷脂(anti-CL)抗体在红斑狼疮(SLE)等疾病中具有血栓形成作用。CL 很容易被氧化(Ox),并在细胞凋亡中发挥作用。在这项工作中,我们研究了 HD 患者中的 IgM 抗-CL 和抗-OxCL。我们进行了一项观察性研究,前瞻性随访了 221 例典型 HD 患者(56%为男性,中位年龄 66(51-74)岁,治疗时间 29(15-58)个月),平均随访时间为 41(20-48)个月),研究了抗-CL、抗-OxCL 与死亡率之间的关系。根据接收者操作特征(ROC)分析,抗-OxCL[曲线下面积(AUC)0·62,P<0·01],而不是抗-CL(AUC 0·52,P=0·2)与死亡率相关。在未经调整和调整后的 Cox 分析中,抗-OxCL 每增加一个对数,全因死亡的风险就会降低[调整后的危害比(HR)0·62(0·43-0·89)]和心血管疾病(CVD)相关死亡的风险[调整后的 HR 0·56(0·32-0·98)]。抗-OxCL 水平低于中位数的患者也有更高的全因死亡和心血管疾病(CVD)相关死亡风险。尽管抗-OxCL 和抗磷酰胆碱(PC)之间存在正相关(ρ=0·57,P<0·01),但这些自身抗体中有一种或两种水平低于中位数的患者,其死亡风险会逐渐增加。抗-OxCL 与β2-糖蛋白 I 无关;抗磷脂抗体综合征患者的抗-CL 依赖于β2-糖蛋白 I,而 HD 患者的抗-CL 则不然。健康供体的血清不依赖于β2-糖蛋白 I。抗-OxCL IgM 与β2-糖蛋白 1(GPI)无关,是一种新的生物标志物;低水平与 HD 患者的死亡相关(高水平与风险降低相关)。与抗-PC 结合可增加这种关联。进一步的治疗意义值得进一步研究。